Gloria Domínguez‐Ortega

Gloria Domínguez‐Ortega

Auto-generated profile, based on publicly available information

Gloria Domínguez‐Ortega

Paediatric Gastroenterology and Nutrition Department Hospital Infantil Universitario Niño Jesús Madrid Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2026 in Digestive and Liver Disease
Verified
Journal Article
Open access
RRRUTH GARCIA ROMERO
RUTH GARCIA ROMERO
GDGloria Domínguez-Ortega
Gloria Domínguez-Ortega
BEBeatriz Espín-Jaime
Beatriz Espín-Jaime
.F.Sonia Fernández‐Cañabate
.Sonia Fernández‐Cañabate
VVVíctor Vila-Miravet
Víctor Vila-Miravet
CGCarolina Gutiérrez-Junquera
Carolina Gutiérrez-Junquera
Real-world paediatric data on dupilumab for eosinophilic esophagitis are scarce. To assess the effectiveness and safety of dupilumab in children and adolescents with eosinophilic esophagitis in routine clinical practice. This retrospective multicentre study included patients younger than 18 years treated with dupilumab in 13 Spanish centres between May 2022 and February 2025. Histological, clinical, patient-reported, endoscopic and safety outcomes were assessed at baseline and follow-up endoscopies. Fifty-one patients were included; median age at dupilumab initiation was 13.7 years (IQR, 12.3-15.0). Most had previously received proton pump inhibitors (88.2%), swallowed topical corticosteroids (84.3%) and elimination diets (70.6%). Histological remission occurred in 30/45 patients (66.7%) at first follow-up and 15/19 (78.9%) at final follow-up. Deep histological remission occurred in 55.6% and 63.2%, respectively. Mean peak eosinophil counts decreased from 67 to 8.5 eosinophils/high-power field (p < 0.001). Symptom scores decreased by >60%, asymptomatic patients increased from 17.6% to 78.9%, and mean endoscopic score decreased from 3.2 to 0.9. Adverse events occurred in 18/51 patients (35.3%), all mild. Dupilumab was effective and well tolerated, with sustained histological, clinical and endoscopic improvement.

24 October 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
SRSilvia Rodríguez‐Manchón
Silvia Rodríguez‐Manchón
TATeresa Alarcón‐Cavero
Teresa Alarcón‐Cavero
AMAlejandro Mira‐Obrador
Alejandro Mira‐Obrador
CGCarolina Gutiérrez‐Junquera
Carolina Gutiérrez‐Junquera
.F.Sonia Fernández‐Cañabate
.Sonia Fernández‐Cañabate
GDGloria Domínguez‐Ortega
Gloria Domínguez‐Ortega

24 August 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PDF file
SRSilvia Rodríguez‐Manchón
Silvia Rodríguez‐Manchón
BEBeatriz Espín
Beatriz Espín
OSOscar Segarra
Oscar Segarra
GDGloria Domínguez‐Ortega
Gloria Domínguez‐Ortega
JBJavier Blasco-Alonso
Javier Blasco-Alonso
JDJuan José Díaz
Juan José Díaz